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Abstract 
Purpose: To develop and validate a fast, sensitive, and simple liquid chromatographic method coupled 
with tandem mass spectrometry for the determination of the potent tyrosine kinase inhibitor, ninetedanib 
(NTB) in plasma, utilizing cyclobenzaprine (CBP) as internal standard (IS). 
Methods: Separation of the two components (NTB and CBP) was performed on a pentafluorophenyl 
(PFP) reversed phase column (50 × 2 mm, 3μm) at ambient temperature using isocratic elution with 
acetonitrile-water (60:40, v/v) containing 0.01 M ammonium formate buffer (pH 4.2) at a flow rate of 0.4 
mL/min. NTB and CBP were monitored by a triple quadrupole tandem mass spectrometer with 
electrospray ionization source in the positive ion mode. The current method was validated following the 
European Medicines Agency (EMA) guidelines 
Results: The proposed method allowed rapid and specific quantification of NTB in the calibration range 
of 2 - 150 ng/mL and determination coefficient of ≥ 0.999. Intra- and inter-day accuracy and precision 
were < 4 % in all cases.  
Conclusion: The developed procedure is rapid, specific, reliable, and validated for quantification of 
NTB in human plasma, and thus can be applied efficiently for the analysis of clinical samples containing 
NTB. 
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Nintedanib (NTB, Figure 1(a)), as a powerful 
tyrosine-kinase inhibitor (TKI), acts by targeting 
numerous pathways for instance fibroblast 
growth factor receptor (FGFR), vascular 
endothelial growth factor receptor (VEGFR)-1n 
and others. NTB therapeutic action is mainly 
related to blockade of ATP- binding pocket that is 
found inside the cell [1]. NTB was approved by 
the FDA (2014) [2] and European Commission 
(2015) for the management of idiopathic 
pulmonary fibrosis (IPF) [3-5]. Additionally, NTB 
was utilized simultaneously with docetaxel in 
treating non-small cell lung cancer (NSCLC) 
patients [6]. 
 
Upon reviewing the literature extensively, it was 
found that few articles were published for NTB 
quantification in rat biological fluids and tissues 
[7-9]. 
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Accordingly, this study was devoted for 
quantification of NTB in spiked human plasma in 
presence of cyclobenzaprine (CBP; IS, Figure 
1(b)) in a very short run time (2 min), which 
permits the analysis of a lot of clinical samples 
containing NTB in a reasonable time. 
Additionally, the current procedure was fully 
validated following the EMA guidelines for 
validation of the bioanalytical method [10]. 
 
 
Figure 1: Chemical structure of a) Nintedanib (NTB) 




Chemicals and reagents 
 
Ninetedanib (NTB) reference powder was 
obtained from LC Laboratories (Woburn, MA, 
USA). Cyclobenzaprine (CBP; IS) reference 
powder, ammonium formate, HPLC-grade 
acetonitrile (ACN) and formic acid were procured 
from Sigma-Aldrich and VWR International (West 
Chester, PA, USA). Purified water was obtained 
from Milli-Q plus purification system, Millipore, 
Waters (Millipore, Bedford, MA, USA). Human 
plasma was kindly supplied by King Khaled 
University Hospital (Riyadh, KSA), after 
approved permissions from donners and it was 
kept frozen at -70 °C until use. 
 
Instrumentation and conditions 
 
Chromatographic separation was conducted on 
an Agilent 1200 series system consisting of 
G1311A binary pump, G1322A degasser, 
G1367B HIP-ALS autosampler, G1316 
thermostatted column compartment (column 
temperature was kept constant at 21 ± 2 ºC), 
G1315 DAD detector and an Agilent 6410 QqQ 
LC/MS (Agilent Technologies, Palo Alto, CA, 
USA).  Chromatographic separation was 
performed on Luna® PFP column (50 × 2 mm, 3 
μm) (Phenomenex, Torrance, CA, USA). The 
flow rate was 0.4 mLmin-1 with a mobile phase 
composed of 40 % water containing 0.01 Molar 
ammonium formate buffer (pH~ 4.2) and 60 % 
acetonitrile (ACN).  Sample injection volume was 
five microliter with a total run time of 2 min. QqQ 
MS detector was utilized for detection of the 
analytes and operated with an ESI interface in 
the positive ionization mode. Nitrogen gas was 
utilized for desolvation (flow rate of 12 L/min) 
while nitrogen gas of high purity was utilized as 
collision gas (pressure = 55 psi). ESI source 
temperature was kept at 350 oC, capillary voltage 
at 4 kV, and dwell time for each ion was 200 ms.  
For quantification purposes, multiple reaction 
monitoring (MRM) was adopted for the 
transitions 540.3→113 for NTB, 276→231 and 
276→84 for CBP (IS). Fragmentor voltage was 
set to 135 and 140 V with collision energy of 25 
and 20 V for NTB and CBP, respectively. Data 
manipulation and acquisition was achieved by 
Agilent MassHunter software. 
 
Preparation of standard solutions  
 
NTB stock standard solution (1.0 mgmL-1) was 
prepared in DMSO. This stock solution was 
further diluted to prepare a working standard 
solution of 1 µgmL-1. For preparation of CBP (IS) 
stock solution, reference CBP powder was 
solubilized in DMSO to produce a concentration 
of 0.1 mgmL-1. One hundred µL of this stock 
solution was diluted to 10 mL with mobile phase 
producing a working solution of 1 µgmL-1. 
 
Sample preparation procedure and 
construction of calibration curve 
 
Fifty microliter of CBP working standard solution 
(1 µgmL-1) was added to different  aliquots of 
NTB working standard solution (1 µgmL-1) and 
diluted to 1 mL with human plasma to prepare 
ten NTB concentrations: 2, 4, 6 (low quality 
control; LQC), 10, 30, 50 (medium quality control; 
MQC), 80, 100 and 120 (high quality control; 
HQC), and 150 ng mL-1.  
 
For extraction of NTB and CBP from plasma 
matrix, one mL of 0.1 M NaOH/glycine buffer 
(pH∼9) was added to 1 mL spiked human 
plasma and the samples were shaken for 60 
seconds.  Three mL of ACN was then added for 
protein precipitation. Precipitated proteins were 
removed by centrifugation at 14000 rpm for 12 
min at 4 oC. Supernatants was filtered through a 
Millex-GP, 0.22 µm syringe filter (Millipore, 
Billerica, MA, USA). The filtered supernatants 
were then loaded in the auto-sampler tray and 
volume of 5 µL were injected into LC-MS/MS. 
Blank was prepared similarly by processing of 
blank human plasma with same procedure but 
using mobile phase instead of NTB aliquots, then 
tested to ensure the absence of interference from 
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any endogenous compounds with NTB and CBP 
peaks.  Calibration curve (2, 4, 6, 10, 30, 50, 80, 
100, 120, and 150 ngmL-1) were generated for 
spiked human plasma samples by drawing the 
peak area ratio of NTB to CBP (y axis) versus 
NTB nominal concentrations (x axis).  Calibration 
samples’ analysis at each concentration was 
attained in triplicates.  Various parameters 
including intercept, determination coefficient (r2) 
and slope were utilized as tools for expressing 
linear regression.  NTB concentrations in spiked 
plasma samples were calculated utilizing the 




Under the previously mentioned chromatographic 
conditions, NTB and CBP were well separated, 
and carryover effect was minimal in either blank 
matrix or blank samples containing CBP alone. 
Figure 2 showed overlaid chromatograms of 
calibration standard solutions of NTB in addition 
to CBP (IS) in plasma matrix samples. 
 
NTB and CBP mass spectra were composed 
mainly of a single ion peaks at m/z 540.3 and 
276.1, respectively. These ions were 
correspondent to the protonated parent ion.  
Isolation of m/z 540.3(NTB) and 276.1(CBP) took 
place in the first mass analyzer (Q1) followed by 
fragmentation (q2) in the collision cell. By 
scanning of the fragments in the second 
analyzer, m/z 113 was detected for NTB while 
m/z 231 and 84 were detected for CPB as shown 
in Figure 3.  For the quantification of NTB and 
CBP, m/z 113 and 231 were selected 
respectively as daughter peak in MRM mode 
because they gave the highest signal intensity. 






The current procedure showed high specificity for 
NTB determination as no interference was 
observed from expected components of plasma 
matrix at the retention time of NTB and/or CBP. 
The mass detector showed no carry over effect 
from samples. NTB and CBP were well 
separated under the optimized chromatographic 
conditions with retention times of 0.92 and 1.65 
min, respectively.  
 
Linearity and sensitivity 
 
The linear regression analysis for the results was 
carried out using the least-square method. The 
results of six calibration curves showed linearity 
in the range of 2-150 ngmL-1 for NTB, with a 
determination coefficient (r2) ≥ 0.9991.  The 
mean calibration curve of NTB standard solutions 
in plasma had the regression equation of y = 
2.5773x + 1.31. The limit of quantitation (LOD) 
and limit of quantification (LOQ) were found to be 
0.32 and 0.97 ngmL-1 in plasma. The standard 
deviation values of each concentration point (six 
replicates) did not exceed 2.91 %. Calibration 
and quality control samples of NTB in human 
plasma (ten points) were back-calculated to 
ensure optimum performance of the proposed 
method. The precision and accuracy for NTB in 
plasma samples were found in the range of 0.85 
to 5.39 % and -3.86 to 2.34 %, respectively 
(Table 1). 
 
Precision and accuracy 
 
The current chromatographic procedure was 
confirmed to be precise and accurate using intra- 
and inter-day precision and accuracy values of 
NTB QC samples. Percentage relative error (% 
RE) and percentage relative standard deviation 
(% RSD) were used for evaluating accuracy and 
precision, respectively.  The values for accuracy 
and precision lied into the suitable range 





Stability studies were performed on QC samples 
under various conditions as stated in Table 3. 
The deviation of the results from the mean value 
of the samples was less than 3.15 % for human 
plasma. Stability results displayed in Table 3 
approved that plasma samples containing NTB 
can be kept under laboratory conditions with no 




Numerous experiments were tried for achieving 
maximum resolution and better separation for 
both NTB and CBP. The selection of the 
composition of the mobile phase was the corner 
stone of these trials; various percentages of ACN 
and water were tried.  Addition of ammonium 
formate (pH ~ 4.2) to the mobile phase allowed 
easy ionization of NTB and CBP in addition to a 
better separation of the two peaks. Accordingly, 
the proportion of 40 % of aqueous solution 
containing 0.01 Molar ammonium formate buffer 
(pH ~ 4.2) and  60 % ACN was  utilized 
isocratically for good separation of the both 
analytes (retention times of 0.92 and 1.65 
minutes for NTB and CBP, respectively), using 
the optimized LC-MS/MS condition.  Run time for 
each run was not more than two min. 
Darwish et al 




Figure 2:  Overlaid MRM chromatograms of NTB and CBP (IS) in spiked human plasma samples 
 
 
Figure 3: MRM Spectra of a) NTB and b) CBP (IS) 
 




Meana Standard deviation (SD) Precision (%) Accuracy (%) 
2 2.02 0.11 5.39 0.95 
4 3.86 0.07 1.74 -3.38 
6 5.93 0.09 1.51 -1.11 
10 10.23 0.10 1.00 2.34 
30 28.84 0.42 1.46 -3.86 
50 50.54 0.64 1.26 1.08 
80 81.73 0.70 0.85 2.17 
100 99.49 0.77 0.77 -0.51 
120 119.42 2.91 2.44 -0.49 
150 149.92 1.38 0.92 -0.05 
a Mean of six determinations 
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Table 2: Intra-day and inter-day precision and accuracy of NTB (QC) samples 
 
Day of analysis NTB measured concentration in plasma 
LQC (6 ng mL-1) MQC (50 ng mL-1) HQC (120 ng mL-1) 
Day 1 
6.10 50.06 119.35 
5.92 50.10 119.53 
6.05 50.47 116.08 
6.01 50.07 115.65 
6.03 50.00 116.13 
5.96 49.86 119.41 
5.96 50.69 116.83 
5.94 50.27 116.41 
5.88 50.00 116.05 
5.81 50.37 120.25 
5.86 51.11 119.08 
5.99 50.46 116.17 
Day 2 
6.13 50.20 118.52 
5.98 49.01 118.85 
6.15 58.21 120.02 
5.95 50.33 119.50 
6.00 49.64 118.77 
5.93 50.15 118.85 
Day 3 
6.17 49.72 116.80 
6.04 48.49 116.60 
6.18 49.50 118.75 
6.00 48.65 118.32 
6.00 49.77 118.14 













Mean 5.96 6.01 50.29 50.21 117.58 118.00 
Standard deviation 
(SD) 0.08 0.10 0.36 1.85 1.76 1.46 
Precision (%RSD) 1.40 1.61 0.71 3.68 1.50 1.24 
Accuracy (%RE) -0.68 0.10 0.58 0.43 -2.02 -1.67 
* Average of twelve determinations of day 1. ** Average of six determinations in three consecutive days. 
 











Accuracy (RE, %) 
Room temp. for 8h   
6 19.35 0.28 1.45 -3.23 
50 148.71 1.62 1.09 -0.86 
120 396.96 3.15 0.79 -0.76 
Three freeze-thaw cycles   
6 18.71 0.40 2.13 -6.45 
50 148.71 1.62 1.09 -0.86 
120 396.96 3.15 0.79 -0.76 
Stored at 4 oC for 24 h     
6 19.04 0.34 1.79 -4.82 
50 148.71 1.62 1.09 -0.86 
120 396.96 3.15 0.79 -0.76 
Stored at -20 oC for 30 days   
6 18.62 0.35 1.87 -6.92 
50 148.71 1.62 1.09 -0.86 
120 397.60 2.19 0.55 -0.60 
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In addition to the optimization of chromatographic 
conditions, mass spectrometric parameters were 
also adjusted for achieving consistent behaviour 
of the parent ions and the major product ions of 
NTB and CBP.  From different modes afforded 
by tanden mass spectrometry, multiple reaction 
monitoring (MRM) mode is advantageous when 
compared to selected ion monitoring (SIM) in 
decreasing matrix effect of plasma as well as 
increasing sensitivity to the analyte of interest. 
Additionally the sensitivity and selectivity were 
enhanced by operating the ionization source 
(ESI) in positive ion mode. 
 
For quantification of NTB and CBP, m/z 113 and 
231 were selected as daughter peaks in MRM 
mode because they gave the highest signal 
intensity. While m/z 84 was utilized as a qualifier 
for CBP. 
 
After method development, validation took place 
in terms of sensitivity, linearity, stability, 
selectivity, accuracy, intra-day and inter-day 
precision, and system suitability.  The method 
validation was developed based on the criteria 
established by the recommendations of the 
European Medicines Agency (EMA) [10]. 
 
The limit of quantitation (LOQ) is the lowest 
concentration of the standard curve which can be 
measured with acceptable accuracy and 
precision for the analyte from human plasma. 
The limit of detection (LOD) and the limit of 
quantitation (LOQ) were calculated based on Eq 
1.   
 
LOQ OR LOD=(k υ)⁄M …………………… (1) 
 
where k equal to 10 and 3.3 for LOQ and LOD 
respectively, υ is the standard deviation of the 
intercept of regression line and M is the slope of 
regression line of the calibration curve. 
 
Intra-day accuracy and precision were evaluated 
by repeated analysis of NTB in human plasma.  
The run consisted of a calibration curve plus 
twelve replicates of each low, medium and high 
quality control (QC) samples (6, 50, 120 ngmL-1). 
Inter-day accuracy and precision were assessed 
by analysis of samples consisting of a calibration 
curve and six replicates of low, medium, and high 
quality control samples for NTB on three 
successive days.  The overall precision of the 
method expressed as relative standard deviation 
and accuracy of the method expressed in term of 
% error which is calculated according to Eq 2. 
 
% Error = [(A-B)/B] x 100 …….………….. (2) 
 
where A is mean measured concentration, B is 
nominal concentration of NTB. 
 
For assessing of NTB stability in plasma matrix, 
six replicates of QC samples were analyzed 
utilizing various storage conditions. Calculation of 
accuracy and precision values were carried out 
using freshly prepared calibration curves in 
plasma matrix. Estimation of NTB bench-top 
stability was done after 8 h of storing NTB QC 
samples at room temperature. Three freeze–
thaw cycles were achieved to estimate NTB 
stability of spiked QC samples after freezing and 
thawing samples at -80 oC and room temperature 
respectively. Moreover, evaluation of NTB 
stability was performed by analyzing the spiked 
QC samples after one day of storing them at 4 o 




A rapid and validated LC-MS/MS method has 
been developed for the quantification of NTB in 
human plasma with good linearity. The assay 
procedure is simple for sample preparation with a 
short run time.  Its elution is eco-friendly with 
regard to reduced consumption of organic 
solvent and low-cost.  The developed method 
should be useful for therapeutic drug monitoring 
of NTB in plasma and thus for further 
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